Max Healthcare Institute Limited is a big player in healthcare. They do a lot of things like running clinics, hospitals, and specialized medical services. Healthcare is super important in India and worldwide. In India, with so many people and diverse health needs, good healthcare is crucial. Globally, the healthcare industry helps tackle health issues everywhere. Max Healthcare is in a good spot to grow because of its role in this important sector.
Max Healthcare’s key role in the growing healthcare industry, it might have a good chance of growing and reaching higher stock prices. It’s like saying Max Healthcare could be a strong player in the stock market game. However, remember, predicting these things is never guaranteed, and it’s crucial to keep an eye on how the company is doing in the market.
About Max Healthcare
Max Healthcare Institute Limited stands at the forefront of healthcare provision, boasting a comprehensive range of services delivered through primary care clinics, multi-speciality hospitals, and super-speciality hospitals. Renowned as India’s second-largest hospital chain, it excels in revenue, EBITDA, and market capitalization.
Max Healthcare is an industry leader, offering complex medical procedures such as transplants, robotic surgeries, cardiac interventions, neurosurgeries, orthopedic procedures, and oncology surgeries. Leveraging state-of-the-art infrastructure, the company employs cutting-edge technologies like Ortho & Spine Robots, Radixact Tomo Therapy, TrueBeam Stx LINAC, Da Vinci Xi Robot, 3.0 Tesla MRI, and Digital PET CT.
The company extends its reach through Max Lab, a non-captive pathology SBU, and Max@Home, delivering quality healthcare services directly to patients’ doorsteps. Max MyHealth, a proprietary digital platform, enhances clinical services accessibility. With 17 facilities and a current capacity of approximately 3,530 beds, Max Healthcare ensures optimal healthcare delivery with an impressive 75% occupancy in H1FY24.
Expanding its global footprint, the company has established ‘Truemax Healthcare’ in Nairobi, Kenya, for international brand promotion. Strategic research collaborations and a strong subsidiary portfolio, including the recent acquisition of Sahara Hospital, Lucknow, underscore Max Healthcare’s commitment to advancing healthcare excellence.
Recent News Around Max Healthcare
- Max Healthcare Institute Limited has a high price-to-book value ratio of 9.49.
- The company has a relatively low return on equity (ROE) of 11.0% over the last 3 years.
- Promoter holding has decreased significantly by 51.5% in the last 3 years.
- Max Healthcare achieved a milestone with the world’s first Desensitization Protocol for Infant ABOi Living Donor Liver Transplantation.
- The company is actively involved in medical education, collaborating with universities for clinical rotations.
- Recent positive developments include a reduction in debt, making the company nearly debt-free.
- Max Healthcare has shown impressive profit growth, with a 115% CAGR over the last 5 years.
- There has been an improvement in debtor days from 38.6 to 26.9 days, indicating better receivables management.
Max Healthcare Q2 Fy2024 Key Points And Summary:
- The company’s Network1 Revenue displayed significant growth, reaching INR 1,779 Cr, reflecting a remarkable 14% YoY increase.
- Operating EBITDA demonstrated commendable growth, registering a 12% YoY increase, totaling INR 471 Cr.
- The Profit After Tax (PAT) for the quarter showed substantial improvement, surging by 26% YoY to INR 338 Cr.
- Gross Revenue for Q3 FY24 amounted to INR 1,779 Cr, marking a notable 14% YoY growth.
- Network Operating EBITDA reached INR 471 Cr, reflecting a positive growth of +12% YoY.
- Operating Margin stood at 27.9%, exhibiting a slight decrease from 28.3% in Q3 FY23 and 28.7% in Q2 FY24.
- EBITDA per bed2 showed improvement, reaching INR 75.6 lakhs in Q3 FY24.
- Cash from Operations3 amounted to INR 226 Cr in Q3 FY24, with INR 137 Cr allocated to ongoing capacity expansion projects and INR 97 Cr paid as dividends.
- Bed occupancy in Q3 FY24 was reported at 73%, with OBD’s lower by ~1% YoY.
- Average Revenue Per Occupied Bed (ARPOB)5 improved to INR 76.8k in Q3 FY24.
- Free treatment was extended to 36,695 patients in OPD and 1,249 patients in IPD from economically weaker sections.
Max Healthcare Share Price Target 2024 To 2030
Max Healthcare Share Price Target 2024
| When | Maximum Price | Minimum Price |
| January 2024 | ₹838.16 | ₹728.83 |
| February 2024 | ₹855.26 | ₹743.71 |
| March 2024 | ₹872.72 | ₹758.89 |
| April 2024 | ₹847.30 | ₹736.78 |
| May 2024 | ₹834.78 | ₹725.89 |
| June 2024 | ₹864.83 | ₹752.03 |
| July 2024 | ₹856.18 | ₹744.51 |
| August 2024 | ₹890.43 | ₹774.29 |
| September 2024 | ₹926.05 | ₹805.26 |
| October 2024 | ₹907.89 | ₹789.47 |
| November 2024 | ₹935.13 | ₹813.15 |
| December 2024 | ₹958.50 | ₹833.48 |
The projected share price targets for Max Healthcare in 2024 reveal critical points that investors should consider. The minimum and maximum prices for each month indicate potential fluctuations. Notably, December 2024 shows a significant expected price range with a maximum of ₹958.50 and a minimum of ₹833.48. This suggests a considerable potential upside for investors.
Investors should note the positive momentum backed by sound fundamentals, making the stock potentially lucrative in the coming year. However, as with any investment, it’s crucial to monitor market dynamics and external factors that may influence the expected price movement.
Max Healthcare Share Price Target 2025
| when | Maximum Price | Minimum Price |
| January 2025 | ₹977.67 | ₹752.06 |
| February 2025 | ₹1,002.74 | ₹771.34 |
| March 2025 | ₹1,041.85 | ₹801.42 |
| April 2025 | ₹1,021.42 | ₹785.71 |
| May 2025 | ₹991.67 | ₹762.82 |
| June 2025 | ₹1,036.30 | ₹797.15 |
| July 2025 | ₹1,015.98 | ₹781.52 |
| August 2025 | ₹1,047.40 | ₹805.69 |
| September 2025 | ₹1,084.06 | ₹833.89 |
| October 2025 | ₹1,112.24 | ₹855.57 |
| November 2025 | ₹1,140.05 | ₹876.96 |
| December 2025 | ₹1,168.55 | ₹898.88 |
In 2025, Max Healthcare’s share price targets reveal a consistent upward trajectory, signaling favorable prospects for potential investors. The monthly projections consistently indicate growth, with both minimum and maximum prices on an ascending trend throughout the year. Notably, December 2025 stands out as a month with a projected peak, reaching a maximum of ₹1,168.55.
This optimistic outlook may be influenced by robust financial performance, strategic initiatives, or positive market conditions. Investors should closely scrutinize these critical points, acknowledging the sustained growth pattern and the potential for a significant year-end surge.
Max Healthcare Share Price Target 2026 To 2030
| Year | Maximum Price (₹) | Minimum Price (₹) |
|---|---|---|
| 2026 | ₹1,226.98 | ₹858.88 |
| 2027 | ₹1,349.67 | ₹944.77 |
| 2028 | ₹1,889.54 | ₹944.77 |
| 2029 | ₹1,635.97 | ₹817.98 |
| 2030 | ₹2,126.76 | ₹1,488.73 |
In the upcoming years from 2026 to 2030, Max Healthcare’s share price targets continue to reflect a positive outlook, projecting sustained growth in both minimum and maximum values. The expected maximum price in 2026 is ₹1,226.98, while the minimum is ₹858.88. This trend continues with an anticipated peak of ₹2,126.76 in 2030 and a minimum of ₹1,488.73 for the same year. These forecasts indicate a consistent upward trajectory, suggesting the company’s resilience and potential for strong financial performance. Investors should consider these projections as part of their comprehensive analysis and market research to make well-informed decisions regarding investment in Max Healthcare over the next five years.
Max Healthcare ‘s Financial Condition (Last 5 Years)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
| Sales + | 1,691 | 1,059 | 2,508 | 3,937 | 4,563 | 5,198 |
| Expenses + | 1,535 | 965 | 2,101 | 2,986 | 3,322 | 3,747 |
| Operating Profit | 156 | 94 | 407 | 951 | 1,241 | 1,451 |
| OPM % | 9.00% | 9.00% | 16.00% | 24% | 27% | 28% |
| Other Income + | 56 | 48 | -122 | 110 | 139 | 173 |
| Interest | 101 | 83 | 179 | 101 | 84 | 59 |
| Depreciation | 103 | 46 | 174 | 221 | 232 | 235 |
| Profit before tax | 8 | 13 | -69 | 739 | 1,064 | 1,330 |
| Tax % | 102% | -1% | -67% | 18% | -4% | |
| Net Profit + | 0 | 59 | -138 | 605 | 1,104 | 1,057 |
| EPS in Rs | -0.06 | 1.1 | -1.42 | 6.24 | 11.37 | 10.88 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% |
Over the past five years, Max Healthcare has exhibited a noteworthy financial performance, reflecting significant growth and resilience. From FY2019 to the trailing twelve months (TTM), the company’s sales have seen a remarkable surge, escalating from ₹1,691 crores to ₹5,198 crores. This impressive upward trajectory in revenue is coupled with a consistent increase in operating profit, reaching ₹1,451 crores with a robust operating profit margin of 28% in the TTM.
While the company faced a challenging period in FY2021 with negative earnings, it swiftly rebounded, reporting a substantial net profit of ₹1,057 crores in the TTM. Max Healthcare’s ability to recover from setbacks and achieve such a positive net profit underscores its adaptability and strategic management.
Moreover, the declining trend in tax percentage over the years, along with a consistent dividend payout of 9%, indicates the company’s effective tax management and commitment to returning value to shareholders. Despite facing fluctuations, Max Healthcare’s financial data suggests a resilient and promising outlook, making it an intriguing prospect for investors seeking stability and growth in the healthcare sector.
FAQS
What is the current market capitalization of Max Healthcare Institute Ltd?
Max Healthcare Institute Ltd has a market capitalization of ₹74,483 Crores.
How does the leadership position of Max Healthcare compare in the Indian healthcare sector?
Max Healthcare is the second-largest hospital chain in India based on revenue, EBITDA, and market capitalization.
What is the current stock price of Max Healthcare Institute Ltd?
The current stock price of Max Healthcare Institute Ltd is ₹766.
What is the high and low price range of Max Healthcare stock in recent times?
The stock has ranged from ₹812 (high) to ₹412 (low).
What is the Price-to-Earnings (P/E) ratio of Max Healthcare stock?
Max Healthcare stock has a Price-to-Earnings ratio of 70.5.
What is the Return on Capital Employed (ROCE) for Max Healthcare?
Max Healthcare has a Return on Capital Employed (ROCE) of 15.0%.
What is the Dividend Yield of Max Healthcare stock?
The Dividend Yield for Max Healthcare stock is 0.13%.
Should one invest in Max Healthcare ?
Max Healthcare Institute Ltd, a prominent player in the healthcare sector, stands as India’s second-largest hospital chain, boasting significant leadership in terms of revenue, EBITDA, and market capitalization. As of February 2, 2024, the stock closed at ₹766, reflecting a 4.57% decrease.
The company demonstrates a robust financial position with a market capitalization of ₹74,483 Crores. It has maintained a stable book value of ₹80.7 and a face value of ₹10. Max Healthcare exhibits a Price-to-Earnings (P/E) ratio of 70.5, indicative of its growth prospects. On the positive side, Max Healthcare has strategically reduced its debt, resulting in almost debt-free status. The company has shown commendable profit growth, posting a 115% CAGR over the last 5 years. However, concerns arise as the stock trades at 9.49 times its book value, and there’s a notable decrease in promoter holding by 51.5% over the last 3 years. The return on equity (ROE) has been relatively low at 16.1%, prompting attention to operational efficiency.
Analyzing the quarterly results, Max Healthcare showcased consistent revenue growth, reaching ₹1,335 Crores in December 2023. The operating profit margin (OPM) improved to 29%, indicating operational efficiency. The net profit for the quarter was ₹289 Crores, demonstrating a positive trend.
Max Healthcare Institute Ltd appears as a resilient player in the healthcare industry, combining operational efficiency with financial stability. While concerns exist, prudent investors may find value in a comprehensive analysis of the company’s performance, balance sheet, and market positioning before making investment decisions.
Leave a Reply